As shown in Figure 6B, we found that pretreatment of breast cancer cells with Migulstat (N-butyldeoxynojirimycin), a drug that blocks the synthesis of GD3, restores CD1d-mediated NKT cell activation. This evidence concerns the gene CD1D and breast cancer.